Article info

Download PDFPDF

Original research
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

Authors

  1. Correspondence to Dr Hiroto Hatakeyama; h-hatakeyama{at}chiba-u.jp
View Full Text

Citation

Kurino T, Matsuda R, Terui A, et al
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

Publication history

  • Accepted December 16, 2019
  • First published February 10, 2020.
Online issue publication 
February 10, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.